693 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
3 Drug Stocks to Report Earnings on Jul 19: JNJ, NVS, NEOG http://www.zacks.com/stock/news/223699/3-drug-stocks-to-report-earnings-on-jul-19-jnj-nvs-neog?cid=CS-ZC-FT-223699 Jul 18, 2016 - Three drug stocks including industry bellwether Johnson & Johnson (JNJ) will report results on Jul 19.
Novartis' Enbrel Biosimilar Gets FDA Panel Recommendation http://www.zacks.com/stock/news/223501/novartis-enbrel-biosimilar-gets-fda-panel-recommendation?cid=CS-ZC-FT-223501 Jul 14, 2016 - Novartis AG (NVS) announced that the FDA's Arthritis Advisory Committee has recommended an approval of the company's proposed biosimilar of Amgen's (AMGN) blockbuster drug, Enbrel (etanercept).
Amgen and Daiichi Sankyo Team Up for Biosimilars in Japan http://www.zacks.com/stock/news/223470/amgen-and-daiichi-sankyo-team-up-for-biosimilars-in-japan?cid=CS-ZC-FT-223470 Jul 14, 2016 - Amgen (AMGN) inked an exclusive agreement with Daiichi Sankyo for the commercialization of nine biosimilars in Japan.
The Zacks Analyst Blog Highlights: Juno, Amgen, AbbVie, Gilead and CytRx http://www.zacks.com/stock/news/223446/the-zacks-analyst-blog-highlights-juno-amgen-abbvie-gilead-and-cytrx?cid=CS-ZC-FT-223446 Jul 14, 2016 - The Zacks Analyst Blog Highlights: Juno, Amgen, AbbVie, Gilead and CytRx
Biotech Stock Roundup: Juno In and Out of Clinical Hold, Amgen Biosimilar Gets Panel Backing http://www.zacks.com/stock/news/223352/biotech-stock-roundup-juno-in-and-out-of-clinical-hold-amgen-biosimilar-gets-panel-backing?cid=CS-ZC-FT-223352 Jul 13, 2016 - Immuno-oncology focused Juno (JUNO) remained in the news with the FDA first placing a clinical hold on a pivotal study and then removing it.
Amgen's Repatha Gains FDA Approval for New Dosing Option http://www.zacks.com/stock/news/223161/amgens-repatha-gains-fda-approval-for-new-dosing-option?cid=CS-ZC-FT-223161 Jul 12, 2016 - Amgen's (AMGN) PCSK9 inhibitor Repatha becomes the first and the only one to gain FDA approval for a monthly single-dose administration.
Amgen (AMGN) Robert A. Bradway on Q1 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3969382-amgen-amgn-robert-bradway-q1-2016-results-earnings-call-transcript?source=feed_all_articles Apr 29, 2016 - Amgen, Inc. (NASDAQ:AMGN)Q1 2016 Earnings CallApril 28, 2016 5:30 pm ETExecutivesArvind K. Sood - Vice President-Investor RelationsRobert A. Bradway - Chairman, President & Chief Executive OfficerDavi
Amgen (AMGN) Q1 2016 Results - Earnings Call Webcast http://seekingalpha.com/article/3969182-amgen-amgn-q1-2016-results-earnings-call-webcast?source=feed_all_articles Apr 28, 2016 - Earnings Conference Call Start time: April 28, 2016 at 17:30 PM ET.The audio will stream live while the call is active and can be replayed upon its completion.
Biotech Stock Roundup: Clinton's Tweet Shakes Biotech Stocks, Amgen In Pipeline-Boosting Deals http://www.zacks.com/stock/news/191100/biotech-stock-roundup-clintons-tweet-shakes-biotech-stocks-amgen-in-pipeline-boosting-deals?cid=CS-ZC-FT-191100 Sep 23, 2015 - Hillary Clinton's tweet about skyrocketing drug prices triggered a sell-off in the biotech sector reflecting concerns regarding the implementation of price control measures.
Stock Market News for September 23, 2015 http://www.zacks.com/stock/news/191065/stock-market-news-for-september-23-2015?cid=CS-ZC-FT-191065 Sep 23, 2015 - Selloff in commodity, auto and biotech stocks dragged benchmarks lower on Tuesday

Pages: 1...626364656667686970

<<<Page 67>